Sydney Lupkin

Her health is better, and she says she's free of the anxiety that came with eating. She's thinking about what she wants to accomplish in 2025.

You know, it could because the FDA just approved ZepBound as the first drug treatment for moderate to severe obstructive sleep apnea in patients who have obesity. Obstructive sleep apnea is a condition in which someone temporarily pauses breathing in their sleep because their upper airway collapses. It is more common among people who have obesity.

You know, it could because the FDA just approved ZepBound as the first drug treatment for moderate to severe obstructive sleep apnea in patients who have obesity. Obstructive sleep apnea is a condition in which someone temporarily pauses breathing in their sleep because their upper airway collapses. It is more common among people who have obesity.

You know, it could because the FDA just approved ZepBound as the first drug treatment for moderate to severe obstructive sleep apnea in patients who have obesity. Obstructive sleep apnea is a condition in which someone temporarily pauses breathing in their sleep because their upper airway collapses. It is more common among people who have obesity.

The new approval could open the door for ZEP-bound coverage by Medicare and Medicaid because it's not just a weight loss drug anymore. So while that's not going to solve everyone's insurance problems here, it could help a lot of people.

The new approval could open the door for ZEP-bound coverage by Medicare and Medicaid because it's not just a weight loss drug anymore. So while that's not going to solve everyone's insurance problems here, it could help a lot of people.

The new approval could open the door for ZEP-bound coverage by Medicare and Medicaid because it's not just a weight loss drug anymore. So while that's not going to solve everyone's insurance problems here, it could help a lot of people.

You bet.

You bet.

You bet.